U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H30O3
Molecular Weight 366.4932
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DROSPIRENONE

SMILES

[H][C@@]12C[C@]1([H])[C@@]3([H])[C@]4([H])[C@]5([H])C[C@]5([H])[C@@]6(CCC(=O)O6)[C@@]4(C)CC[C@]3([H])[C@@]7(C)CCC(=O)C=C27

InChI

InChIKey=METQSPRSQINEEU-HXCATZOESA-N
InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1

HIDE SMILES / InChI

Molecular Formula C24H30O3
Molecular Weight 366.4932
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 10
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/7625729 | https://www.ncbi.nlm.nih.gov/pubmed/23530659 | https://www.ncbi.nlm.nih.gov/pubmed/7107766 | http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021355s006lbl.pdf

Drospirenone (INN, USAN), also known as 1,2-dihydrospirorenone, is a steroidal progestin of the spirolactone group. Drospirenone binds strongly to the progesterone receptor (PR) and mineralocorticoid receptor (MR), with lower affinity, to the androgen receptor (AR), and very low affinity for the glucocorticoid receptor (GR). Drospirenone is an ingredient in some birth control pills and hormone replacement therapy. In combination with ethinylestradiol it is used as contraception, and for women who want contraception it is also approved by the U.S. Food and Drug Administration (FDA) to treat vasomotor symptoms due to menopause.It is sold as a combined oral contraceptive under the brand names Yasmin (US, EU, Latin America), Jasmine (France), Yarina (Russia) in a dosage containing drospirenone 3 mg/ethinylestradiol 30 µg. In the United States, Bayer Schering released a pill based on Yasmin with the B vitamin folate (B9), which is marketed under the names Safyral and Beyaz.

Originator

Curator's Comment: # Bayer HealthCare Pharmaceuticals

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
YASMIN

Approved Use

INDICATIONS AND USAGE. Yasmin is an estrogen/progestin COC indicated for use by women to prevent pregnancy

Launch Date

9.8953921E11
Primary
Angeliq

Approved Use

Indications and Usage ANGELIQ is indicated in women who have a uterus for the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.

Launch Date

1.12777914E12
Primary
Angeliq

Approved Use

Indications and Usage ANGELIQ is indicated in women who have a uterus for the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.

Launch Date

1.12777914E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
62.5 ng/mL
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
9.85 ng/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
33.9 ng/mL
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
27 ng/mL
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
41 ng/mL
4 mg 1 times / day steady-state, oral
dose: 4 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1007 ng × h/mL
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
140 ng × h/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
506 ng × h/mL
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
26.3 h
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
25.5 h
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
28.5 h
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
30 h
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
30 h
4 mg 1 times / day steady-state, oral
dose: 4 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
4%
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
healthy, 17 - 40 years
n = 2837
Health Status: healthy
Age Group: 17 - 40 years
Sex: F
Population Size: 2837
Sources:
Disc. AE: Premenstrual syndrome, Migraine headache...
Other AEs: Premenstrual syndrome, Migraine headache...
AEs leading to
discontinuation/dose reduction:
Premenstrual syndrome (6.7%)
Migraine headache (1.5%)
Other AEs:
Premenstrual syndrome (13.2%)
Migraine headache (10.7%)
Breast discomfort (8.3%)
Nausea and vomiting (4.5%)
Abdominal discomfort (2.3%)
Mood change (2.3%)
Sources:
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Co-administed with::
ethinylestradiol(20 mug)
Sources:
healthy, mean 25.1 years
n = 220
Health Status: healthy
Age Group: mean 25.1 years
Sex: F
Population Size: 220
Sources:
Disc. AE: Weight gain, Headache...
AEs leading to
discontinuation/dose reduction:
Weight gain (> 0.45)
Headache (> 0.45)
Depression (> 0.45)
Menorrhagia (> 0.45)
Skin disorder (> 0.45)
Emotional lability (> 0.45)
Sources:
AEs

AEs

AESignificanceDosePopulation
Migraine headache 1.5%
Disc. AE
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
healthy, 17 - 40 years
n = 2837
Health Status: healthy
Age Group: 17 - 40 years
Sex: F
Population Size: 2837
Sources:
Migraine headache 10.7%
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
healthy, 17 - 40 years
n = 2837
Health Status: healthy
Age Group: 17 - 40 years
Sex: F
Population Size: 2837
Sources:
Premenstrual syndrome 13.2%
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
healthy, 17 - 40 years
n = 2837
Health Status: healthy
Age Group: 17 - 40 years
Sex: F
Population Size: 2837
Sources:
Abdominal discomfort 2.3%
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
healthy, 17 - 40 years
n = 2837
Health Status: healthy
Age Group: 17 - 40 years
Sex: F
Population Size: 2837
Sources:
Mood change 2.3%
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
healthy, 17 - 40 years
n = 2837
Health Status: healthy
Age Group: 17 - 40 years
Sex: F
Population Size: 2837
Sources:
Nausea and vomiting 4.5%
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
healthy, 17 - 40 years
n = 2837
Health Status: healthy
Age Group: 17 - 40 years
Sex: F
Population Size: 2837
Sources:
Premenstrual syndrome 6.7%
Disc. AE
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
healthy, 17 - 40 years
n = 2837
Health Status: healthy
Age Group: 17 - 40 years
Sex: F
Population Size: 2837
Sources:
Breast discomfort 8.3%
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
healthy, 17 - 40 years
n = 2837
Health Status: healthy
Age Group: 17 - 40 years
Sex: F
Population Size: 2837
Sources:
Depression > 0.45
Disc. AE
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Co-administed with::
ethinylestradiol(20 mug)
Sources:
healthy, mean 25.1 years
n = 220
Health Status: healthy
Age Group: mean 25.1 years
Sex: F
Population Size: 220
Sources:
Emotional lability > 0.45
Disc. AE
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Co-administed with::
ethinylestradiol(20 mug)
Sources:
healthy, mean 25.1 years
n = 220
Health Status: healthy
Age Group: mean 25.1 years
Sex: F
Population Size: 220
Sources:
Headache > 0.45
Disc. AE
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Co-administed with::
ethinylestradiol(20 mug)
Sources:
healthy, mean 25.1 years
n = 220
Health Status: healthy
Age Group: mean 25.1 years
Sex: F
Population Size: 220
Sources:
Menorrhagia > 0.45
Disc. AE
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Co-administed with::
ethinylestradiol(20 mug)
Sources:
healthy, mean 25.1 years
n = 220
Health Status: healthy
Age Group: mean 25.1 years
Sex: F
Population Size: 220
Sources:
Skin disorder > 0.45
Disc. AE
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Co-administed with::
ethinylestradiol(20 mug)
Sources:
healthy, mean 25.1 years
n = 220
Health Status: healthy
Age Group: mean 25.1 years
Sex: F
Population Size: 220
Sources:
Weight gain > 0.45
Disc. AE
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Co-administed with::
ethinylestradiol(20 mug)
Sources:
healthy, mean 25.1 years
n = 220
Health Status: healthy
Age Group: mean 25.1 years
Sex: F
Population Size: 220
Sources:
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
minimum
minimum
moderate [IC50 31200 uM]
no (co-administration study)
Comment: "IC50 units given are ""mM""; no significant effect of DRSP on the systemic clearance of the CYP3A4 product omeprazole sulfone was found"
Page: 25.0
moderate [IC50 36500 uM]
yes [IC50 14500 uM]
yes [IC50 3390 uM]
no (co-administration study)
Comment: "IC50 units given are ""mM""; daily oral administration of 3 mg DRSP for 14 days did not affect the oral clearance of omeprazole (40 mg, single oral dose) and the CYP2C19 product 5-hydroxy omeprazole"
Page: 25.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
no (co-administration study)
Comment: simvastatin is not expected to affect DRSP's metabolism; When tested with midazolam, PK parameters of midazolam were similar regardless whether it was dosed with DSRP or with placebo.
Page: 25.0
PubMed

PubMed

TitleDatePubMed
Dihydrospirorenone (ZK30595): a novel synthetic progestagen--characterization of binding to different receptor proteins.
1992 Dec
New drugs 2002. Part II.
2002 Apr
Dutch GPs warned against new contraceptive pill.
2002 Apr 13
Is [symbol: see text] Yasmin a "truly different" pill?
2002 Aug
Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder.
2002 Dec
Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone.
2002 Dec
Yasmin: the reason why.
2002 Dec
The renin-aldosterone system and drospirenone.
2002 Feb
Systematic optimisation of high-performance liquid chromatographic separation by varying the temperature, gradient, and stationary phase.
2002 Jan
A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms.
2002 Jan
Quality of life issues. Potential role for an oral contraceptive containing ethinyl estradiol and drospirenone.
2002 Nov
Update and future of systemic acne treatment.
2003
Classification and pharmacology of progestins.
2003 Dec 10
Yasmin advert withdrawn--why and how.
2003 Mar
Androgens and antiandrogens.
2003 Nov
Hormone therapy and the cardiovascular system: the critical role of progestins.
2003 Oct
New progestogens: a review of their effects in perimenopausal and postmenopausal women.
2004
Rationale for new oral contraceptive dosing.
2004 Jan-Feb
Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study.
2004 Jun
Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate.
2004 Nov
Short-term variations in bone remodeling markers of an oral contraception formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol: observational study in young postadolescent women.
2004 Oct
Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy.
2005 Jan
Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.
2005 Nov-Dec
Effects of drospirenone/estrogen combinations on bone metabolism.
2005 Oct
Added benefits of drospirenone for compliance.
2005 Oct
Gateways to clinical trials.
2005 Sep
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021355s006lbl.pdf
To prevent pregnancy: One tablet (containing 3 mg drospirenone and 0.03 mg ethinyl estradiol) daily by mouth at the same time every day. To prevent symptoms due to menopause. one tablet (0.25 mg drospirenone/0.5 mg ethinyl estradiol) taken by mouth once daily
Route of Administration: Oral
In Vitro Use Guide
Activity of drospirenone was investigated by transiently transfecting the human MR (pRShMR) and pMMTV-CAT into COS 1 cells. Cells were treated with 10 nmol/l aldosterone and, in addition, with increasing amounts of the drospirenone (1nM – 1 mkM). After 48 hrs cells were harvested and duplicate dishes were assayed for activity
Substance Class Chemical
Created
by admin
on Sat Dec 16 18:02:01 UTC 2023
Edited
by admin
on Sat Dec 16 18:02:01 UTC 2023
Record UNII
N295J34A25
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DROSPIRENONE
EP   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
DROSPIRENONE [USP MONOGRAPH]
Common Name English
NSC-760103
Code English
DROSPIRENONE [MART.]
Common Name English
DROSPIRENONE COMPONENT OF SAFYRAL
Common Name English
DROSPIRENONE COMPONENT OF YASMIN
Common Name English
(6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)-1,3',4',6,6A,7,8,9,10,11,12,13,14,15,15A,16-HEXADECAHYDRO-10,13-DIMETHYLSPIRO-(17H-DICYCLOPROPA(6,7:15,16)CYCLOPENTA(A)PHENANTHRENE-17,2'(5'H)-FURAN)-3,5'(2H)-DIONE
Common Name English
DROSPIRENONE COMPONENT OF NEXTSTELLIS
Brand Name English
DROSPIRENONE COMPONENT OF YAZ
Common Name English
DROSPIRENONE [MI]
Common Name English
SLYND
Brand Name English
drospirenone [INN]
Common Name English
ANGELIQ COMPONENT DROSPIRENONE
Common Name English
ZK-30595
Code English
DROSPIRENONE [USP-RS]
Common Name English
YASMIN COMPONENT DROSPIRENONE
Common Name English
YAZ COMPONENT DROSPIRENONE
Common Name English
BEYAZ COMPONENT DROSPIRENONE
Common Name English
DROSPIRENONE [JAN]
Common Name English
DROSPIRENONE [EP MONOGRAPH]
Common Name English
DROSPIRENONE COMPONENT OF BEYAZ
Common Name English
SAFYRAL COMPONENT DROSPIRENONE
Common Name English
DROSPIRENONE COMPONENT OF ANGELIQ
Common Name English
DROSPIRENONE [USAN]
Common Name English
DROSPIRENONE [VANDF]
Common Name English
17-Hydroxy-6β,7β:15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21-carboxylic acid, γ-lactone
Common Name English
ZK 30595
Code English
DROSPIRENONE [ORANGE BOOK]
Common Name English
Drospirenone [WHO-DD]
Common Name English
NEXTSTELLIS COMPONENT DROSPIRENONE
Brand Name English
DRSP
Common Name English
Classification Tree Code System Code
WHO-ATC G03AC10
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
WHO-ATC G03AA12
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
NDF-RT N0000011301
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
NDF-RT N0000175602
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
LIVERTOX 333
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
WHO-ATC G03FA17
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
NCI_THESAURUS C776
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
WHO-VATC QG03FA17
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
WHO-VATC QG03AA12
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
Code System Code Type Description
INN
6519
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
PRIMARY
RXCUI
11636
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
PRIMARY RxNorm
CHEBI
50838
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
PRIMARY
RS_ITEM_NUM
1229409
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
PRIMARY
NCI_THESAURUS
C47502
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
PRIMARY
CAS
67392-87-4
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
PRIMARY
NSC
760103
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
PRIMARY
LACTMED
Drospirenone
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
PRIMARY
FDA UNII
N295J34A25
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
PRIMARY
IUPHAR
2874
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
PRIMARY
EVMPD
SUB06413MIG
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
PRIMARY
MERCK INDEX
m4772
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
PRIMARY Merck Index
DAILYMED
N295J34A25
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
PRIMARY
WIKIPEDIA
Drospirenone
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
PRIMARY
EPA CompTox
DTXSID7046465
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
PRIMARY
PUBCHEM
68873
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
PRIMARY
ECHA (EC/EINECS)
266-679-2
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
PRIMARY
DRUG BANK
DB01395
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
PRIMARY
SMS_ID
100000092375
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
PRIMARY
USAN
JJ-45
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
PRIMARY
HSDB
7896
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
PRIMARY
DRUG CENTRAL
968
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
PRIMARY
MESH
C035144
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
PRIMARY
ChEMBL
CHEMBL1509
Created by admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Related Record Type Details
METABOLITE INACTIVE -> PARENT
MAJOR
PLASMA
METABOLITE INACTIVE -> PARENT
MAJOR
PLASMA
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
at 195 nm
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY